Northwest Biotherapeutics (NWBO) Total Current Liabilities (2016 - 2025)
Historic Total Current Liabilities for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to $87.9 million.
- Northwest Biotherapeutics' Total Current Liabilities rose 4758.08% to $87.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $87.9 million, marking a year-over-year increase of 4758.08%. This contributed to the annual value of $68.3 million for FY2024, which is 5103.53% up from last year.
- Latest data reveals that Northwest Biotherapeutics reported Total Current Liabilities of $87.9 million as of Q3 2025, which was up 4758.08% from $83.9 million recorded in Q2 2025.
- Northwest Biotherapeutics' 5-year Total Current Liabilities high stood at $363.4 million for Q1 2021, and its period low was $39.9 million during Q2 2023.
- Its 5-year average for Total Current Liabilities is $122.4 million, with a median of $83.9 million in 2025.
- As far as peak fluctuations go, Northwest Biotherapeutics' Total Current Liabilities soared by 81633.42% in 2021, and later crashed by 7278.74% in 2022.
- Northwest Biotherapeutics' Total Current Liabilities (Quarter) stood at $133.8 million in 2021, then decreased by 5.8% to $126.0 million in 2022, then crashed by 64.13% to $45.2 million in 2023, then skyrocketed by 51.04% to $68.3 million in 2024, then increased by 28.75% to $87.9 million in 2025.
- Its Total Current Liabilities stands at $87.9 million for Q3 2025, versus $83.9 million for Q2 2025 and $83.1 million for Q1 2025.